Spectrum Pharmaceuticals SPPI announced today the that the
company has submitted a New Drug Application (NDA) to the U.S. Food and
Drug Administration (FDA) for approval of Belinostat, a pan-histone
deacetylase (HDAC) inhibitor, for the treatment of patients with
relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). Belinostat
is differentiated from other HDAC inhibitors that selectively inhibit a
single class of HDAC enzymes by virtue of its inhibition of all 3
classes of the zinc-dependent HDAC enzymes (Class I, Class II and Class
IV); this leads to different alterations in histone and non-histone
protein acetylation that, in turn, could importantly influence chromatin
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in